Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CureVac NV CVAC

Healthcare Biotechnology
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.

Recent & Breaking News (NDAQ:CVAC)

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update

Accesswire November 12, 2024

CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024

Accesswire November 7, 2024

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer

Accesswire November 4, 2024

CureVac to Present at the 12th International mRNA Health Conference

Accesswire November 4, 2024

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Accesswire October 28, 2024

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Accesswire September 13, 2024

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Accesswire September 12, 2024

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Accesswire September 9, 2024

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Accesswire August 15, 2024

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

Accesswire August 15, 2024

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Accesswire August 15, 2024

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

Accesswire July 11, 2024

GSK and CureVac to Restructure Collaboration into New Licensing Agreement

Accesswire July 3, 2024

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities

Accesswire July 3, 2024

CureVac Announces Voting Results of General Meeting

Accesswire June 24, 2024

CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK

Accesswire May 28, 2024

CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update

Accesswire May 23, 2024

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Accesswire April 24, 2024

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Accesswire April 24, 2024

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Accesswire April 24, 2024